GSK plc (GSK) |
| 59.18 0.24 (0.41%) 04-14 16:00 |
| Open: | 58.92 |
| High: | 59.57 |
| Low: | 58.14 |
| Volume: | 3,583,634 |
| Market Cap: | 118,672(M) |
| PE Ratio: | 15.91 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 69.58 |
| Resistance 1: | 59.57 |
| Pivot price: | 56.12 |
| Support 1: | 54.61 |
| Support 2: | 51.55 |
| 52w High: | 61.7 |
| 52w Low: | 35.08 |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
| EPS | 3.710 |
| Book Value | 5.440 |
| PEG Ratio | 0.00 |
| Gross Profit | 11.860 |
| Profit Margin (%) | 17.50 |
| Operating Margin (%) | 18.93 |
| Return on Assets (ttm) | 9.8 |
| Return on Equity (ttm) | 43.3 |
Tue, 14 Apr 2026
Rockville R&D campus loan in special servicing as GSK prepares to vacate - The Business Journals
Tue, 14 Apr 2026
GSK plc stock (GB0009252882): Is its vaccines and specialty medicines focus strong enough to unlock - AD HOC NEWS
Tue, 14 Apr 2026
GSK (GLAXF) leaders receive Ordinary Shares via Share Reward Plan - Stock Titan
Tue, 14 Apr 2026
GSK Executives Acquire Shares Under Company Reward Plan - TipRanks
Tue, 14 Apr 2026
Share buyback adds 325,000 GSK (GSK) shares to treasury stock - Stock Titan
Sun, 12 Apr 2026
GSK bets big on cancer comeback with aggressive trial push (GSK:NYSE) - Seeking Alpha
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |